Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.97% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 20.07B.
Undervalued
The company’s latest PE is 18.44, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.40B shares, decreasing 1.09% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 5.22M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.31.